Loading...
01/11 15:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session reveal a mixed outlook. Positive elements include stable fiscal year '26 guidance, potential growth from AI capabilities, and interest in acquisitions. However, challenges such as a significant drop in Pro-ficiency software revenue, cautious large pharma, and current renewal rates in the low to mid-80% range offset these positives. The lack of significant changes in guidance assumptions and the absence of major cancellations provide stability, but the overall sentiment remains neutral due to the balancing of positive and negative factors.
Total Revenue (Q4) $17.5 million, a decrease of 6% year-over-year. The decline was attributed to market conditions and client consolidations.
Total Revenue (Fiscal Year) $79.2 million, an increase of 13% year-over-year. Growth was driven by increases in both software and services revenue.
Software Revenue (Q4) Decreased 9%, representing 52% of total revenue. Decline due to market conditions and client consolidations.
Software Revenue (Fiscal Year) Increased 12%, representing 58% of total revenue. Growth driven by product performance and client demand.
Services Revenue (Q4) Decreased 3%, representing 48% of total revenue. Decline due to expected market conditions.
Services Revenue (Fiscal Year) Increased 15%, representing 42% of total revenue. Growth primarily due to the addition of the Med Comm business.
Gross Margin (Fiscal Year) 58%, down from 62% last year. Software gross margin was 79% (down from 84%), and services gross margin remained at 30%. Decline in software gross margin was due to increased amortization expenses.
Net Loss (Fiscal Year) $64.7 million, compared to net income of $10 million last year. Loss includes a $77.2 million noncash impairment charge.
Adjusted Diluted EPS (Fiscal Year) $1.03, an increase from $0.95 last year. Growth reflects operational improvements.
Adjusted EBITDA (Fiscal Year) $22 million, an increase from $20.3 million last year. Growth driven by revenue increases and operational efficiency.
Cash and Short-Term Investments (End of Fiscal Year) $32.4 million, with no debt and strong free cash flow.
GastroPlus 10.2: Released earlier this year as part of the groundwork for future biosimulation capabilities.
Integrated Product Ecosystem: Combines validated science, cloud-scale performance, and AI-driven services into a unified ecosystem for discovery, clinical development, and commercialization.
Biosimulation Demand: Momentum behind biosimulation is accelerating as biopharma and regulatory partners scale internal model development capabilities and invest in AI and digital infrastructure.
Client Budget Stabilization: Signs of stabilization in client budgets as large pharma gains visibility into pricing frameworks and biotech funding improves modestly.
Unified Operating Model: Transitioned to a unified operating model aligning product, technology, R&D, consulting, and business development into a client-focused structure.
Revenue and Client Metrics: Fiscal year revenue grew 13% to $79.2 million, with an average revenue per client of $143,000 and an 88% renewal rate.
Strategic Reset: 2025 marked a strategic reset with a focus on integrating scientific engines, cloud infrastructure, and AI capabilities into a biosimulation ecosystem.
Future Roadmap: Plans to share more details about the integrated product strategy and roadmap at the virtual Investor Day in January 2026.
Client Budget Pressures: Client budgets were pressured by broader pharmaceutical headwinds, including the threat of tariffs and most favored nation pricing implementation, causing disruptions starting midyear.
Market Uncertainty: Uncertainty in the overall environment is expected to persist in the near term, despite early signs of stabilization in large pharma pricing frameworks and modest improvement in biotech funding.
Decline in Software Revenue: Software revenue decreased 9% in the fourth quarter, with specific declines in products like ADMET Predictor and GastroPlus, attributed to market conditions and client consolidations.
Services Revenue Challenges: Services revenue for certain solutions, such as PBPK and QSP services, declined significantly for the quarter and fiscal year, reflecting challenges in maintaining growth in these areas.
Gross Margin Decline: Total gross margin decreased to 58% from 62% in the prior year, primarily due to increased amortization expenses related to acquisitions and software development costs.
Noncash Impairment Charge: A $77.2 million noncash impairment charge significantly impacted total operating expenses, increasing them to 148% of revenue compared to 53% last year.
First Quarter Revenue Decline Expectation: First quarter revenue for fiscal 2026 is anticipated to be 3% to 5% lower than the same period last year, reflecting ongoing market challenges.
Market Conditions and Client Spending: The company expects fiscal year 2026 market conditions to resemble those at the close of fiscal year 2025, with a stable operating environment. However, should market conditions improve and clients increase spending, the company is prepared to respond.
Revenue Guidance for Fiscal Year 2026: Total revenue is projected to be between $79 million to $82 million, representing year-over-year growth of 0% to 4%.
Revenue Mix: The software mix is expected to range between 57% to 62% of total revenue.
Adjusted EBITDA Margin: The adjusted EBITDA margin is anticipated to be between 26% to 30%.
Adjusted Diluted Earnings Per Share: Adjusted diluted EPS is projected to be between $1.03 to $1.10.
First Quarter Revenue Guidance: First quarter revenue is expected to be approximately 3% to 5% lower than the same period last year.
Tax Rate for Fiscal Year 2026: The effective tax rate is expected to be in the range of 12% to 14%.
Product and Strategy Development: The company plans to focus on integrating its scientific engines, cloud infrastructure, and AI capabilities into a unified biosimulation ecosystem. This includes updates across products like GastroPlus, MonolixSuite, ADMET Predictor, and others in fiscal 2026.
Client and Market Trends: Clients are increasingly adopting biosimulation as a core component of R&D, with a focus on faster cycle times, AI-assisted workflows, and regulatory-grade modeling. The company is positioned to address these needs with its integrated product ecosystem.
The selected topic was not discussed during the call.
The earnings call summary presents a mixed outlook. While there is positive news about software performance peaking and MedCom exceeding expectations, challenges exist with clinical operations software revenue and tough comparisons. The Q&A section reveals cautious optimism with no change in guidance and AI integration showing promise. However, management's avoidance of specific details and the lack of new verticals or products in the near term suggest limited immediate catalysts. Consequently, the stock is likely to remain neutral over the next two weeks.
The earnings call summary and Q&A session reveal a mixed outlook. Positive elements include stable fiscal year '26 guidance, potential growth from AI capabilities, and interest in acquisitions. However, challenges such as a significant drop in Pro-ficiency software revenue, cautious large pharma, and current renewal rates in the low to mid-80% range offset these positives. The lack of significant changes in guidance assumptions and the absence of major cancellations provide stability, but the overall sentiment remains neutral due to the balancing of positive and negative factors.
The earnings call reveals several concerns: a revenue drop and margin erosion in the fourth quarter, declining renewal rates, and cautious client spending. Although there are positive aspects like growth in GastroPlus and AI initiatives, these are overshadowed by overall financial struggles and unclear management guidance. The negative sentiment is further supported by declining service revenues and uncertain market conditions, suggesting a likely negative stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
